 |
| |
DNAvaccine.com mailing list
To get on the DNAvaccine.com mailing list, please email me at peratt@aldevron.com . The mailing list is a good way to find out the latest information about new technology, upcoming conference, or just general information that you may find resourceful for your day to day experiments.
I hope to hear from you soon. |
|
|
Vical to Present at Upcoming Investor Conferences
|
|
Posted by administrator on Monday, May 12 @ 05:47:52 PDT (10 reads)
Vical's President and Chief Executive Officer,
Vijay B. Samant, will provide an overview of the company's technologies,
development programs, and strategic partnerships at three upcoming investor
conferences.
Read More...
(Read More... | Score: 0)
|
|
Therapeutic DNA Vaccine Company Inovio Biomedical Reports First Quarter 2008 Financial Results
|
|
Posted by administrator on Friday, May 09 @ 19:15:31 PDT (21 reads)
Total revenue for the quarter ended March 31, 2008, was $653,000, compared with $504,000 for the same period in 2007.
Read More...
(Read More... | Score: 0)
|
|
Vical Reports First Quarter 2008 Financial Results and Updates Key Development Programs
|
|
Posted by administrator on Thursday, May 08 @ 11:57:55 PDT (19 reads)
Vical had cash and investments of $60 million at March 31, 2008. The
company's first quarter 2008 financial results were consistent with its
projection for a full year net loss of between $32 million and $37 million
and a net cash burn of $27 million to $32 million.
Read More...
(Read More... | Score: 0)
|
|
DOR BioPharma Acquires Option for Anthrax Vaccine
|
|
Posted by administrator on Thursday, May 08 @ 11:45:43 PDT (19 reads)
The option, which was obtained through Harvard University's Office of Technology Development, involves an issued U.S. patent that covers variants of an antigen developed in a Harvard Medical School laboratory, according to DOR.
Read More...
(Read More... | Score: 0)
|
|
Novartis Corporation Menveo Vaccine Shows Superior Immune Response
|
|
Posted by administrator on Tuesday, May 06 @ 10:51:09 PDT (36 reads)
These data build on previous studies that demonstrated Menveo generates a strong protective immune response against these four vaccine-preventable serogroups in people across age groups from infancy to adulthood. Novartis expects to submit a Biologics License Application (BLA) to the US Food and Drug Administration later this year.
Read More...
(Read More... | Score: 0)
|
| |
| |
